The multidisciplinary approach to the treatment of rectal cancer: 2015 Update

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 4, 2015, Pages 507-517

  Onyeuku, Nasarachi E ^a   Ayala Peacock, Diandra N ^a   Russo, Suzanne M ^b   Blackstock, A William ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b University of South AL   (United States)

Author keywords

Adjuvant; Cancer; Chemotherapy; Imaging; Radiation; Rectal; Surgery; Targeted therapies

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; SEMUSTINE;

ADJUVANT CHEMORADIOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENDOSCOPIC SURGERY; HIGH RISK POPULATION; HUMAN; LAPAROSCOPIC SURGERY; LOCAL RECURRENCE FREE SURVIVAL; MINIMALLY INVASIVE SURGERY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; RECTUM SURGERY; RECURRENCE RISK; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; COOPERATION; INTERDISCIPLINARY COMMUNICATION; MORTALITY; MULTIMODALITY CANCER THERAPY; PATIENT CARE; PATIENT SELECTION; PREDICTIVE VALUE; RECTAL NEOPLASMS;

COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; HUMANS; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE TEAM; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84924373629     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.987753     Document Type: Review

References (95)

1. Cancer facts & figures 2013, 2013, American Cancer Society Atlanta
2. Ayala DN, Russo SM, Blackstock AW. Multidisciplinary treatment of resectable rectal cancer. Expert Rev Gastroenterol Hepatol 2009;3(4):383-94
3. Tan CH, Iyer R. Use of computed tomography in the management of colorectal cancer. World J Radiol 2010;2(5):151-8
4. O'Neill BD, Salerno G, Thomas K, et al. MR vs CT imaging: low rectal cancer tumour delineation for three-dimensional conformal radiotherapy. Br J Radiol 2009;82(978):509-13
5. Bellows CF, Jaffe B, Bacigalupo L, et al. Clinical significance of magnetic resonance imaging findings in rectal cancer. World J Radiol 2011;3(4):92-104
6. Taylor FG, Quirke P, Heald RJ, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014;32(1):34-43
7. Hunerbein M, Pegios W, Rau B, et al. Prospective comparison of endorectal ultrasound, three-dimensional endorectal ultrasound, and endorectal MRI in the preoperative evaluation of rectal tumors. Preliminary results. Surg Endosc 2000;14(11):1005-9
8. Samee A, Selvasekar CR. Current trends in staging rectal cancer. World J Gastroenterol 2011;17(7):828-34
9. Puli SR, Bechtold ML, Reddy JB, et al. Can endoscopic ultrasound predict early rectal cancers that can be resected endoscopically? A meta-analysis and systematic review. Dig Dis Sci 2010;55(5):1221-9
10. Tatli S, Mortele KJ, Breen EL, et al. Local staging of rectal cancer using combined pelvic phased-array and endorectal coil MRI. J Magn Reson Imaging 2006;23(4):534-40
11. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1(8496):1479-82
12. Ridgway PF, Darzi AW. The role of total mesorectal excision in the management of rectal cancer. Cancer Contr 2003;10(3):205-11
13. Farid H, O'Connell TX. Methods to decrease the morbidity of abdominoperineal resection. Am Surg 1995;61(12):1061-4
14. Perry WB, Connaughton JC. Abdominoperineal resection: how is it done and what are the results? Clin Colon Rectal Surg 2007;20(3):213-20
15. Ogilvie JW, Ricciardi R. Complications of perineal surgery. Clin Colon Rectal Surg 2009;22(1):51-9
16. Kim JH, Noh TI, Oh MM, et al. Voiding dysfunction after total mesorectal excision in rectal cancer. Int Neurourol J 2011;15(3):166-71
17. Wibe A, Syse A, Andersen E, et al. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis Colon Rectum 2004;47(1):48-58
18. Nagtegaal ID, van de Velde CJ, Marijnen CA, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol 2005;23(36):9257-64
19. National Institute for Health and Clinical Excellence (NICE). Laparoscopic surgery for colorectal cancer: review of NICE technology appraisal 17. NICE: London, 2006
20. Row D, Weiser MR. An update on laparoscopic resection for rectal cancer. Cancer Contr 2010;17(1):16-24
21. Guillou PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005;365(9472):1718-26
22. Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol 2007;25(21):3061-8
23. Green BL, Marshall HC, Collinson F, et al. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg 2013;100(1):75-82
24. Ng SS, Leung KL, Lee JF, et al. Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: a prospective randomized trial. Ann Surg Oncol 2008;15(9):2418-25
25. van der Pas MH, Haglind E, Cuesta MA, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013;14(3):210-18
26. Fleshman JW. A Phase III Prospective Randomized Trial Comparing Laparoscopic-assisted Resection Versus Open Resection for Rectal Cancer. NCT00726622), 2013
27. Stevenson A. Australasian Laparoscopic Cancer of the Rectum Trial: A phase III prospective randomised trial comparing laparoscopic-assisted resection versus open resection for rectal cancer. Available from: www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=308213 2014
28. Heidary B, Phang TP, Raval MJ, et al. Transanal endoscopic microsurgery: a review. Can J Surg 2014;57(2):127-38
29. Serra-Aracil X, Mora-Lopez L, Alcantara-Moral M, et al. Transanal endoscopic surgery in rectal cancer. World J Gastroenterol 2014;20(33):11538-45
30. Paty PB, Nash GM, Baron P, et al. Long-term results of local excision for rectal cancer. Ann Surg 2002;236(4):522-9; discussion 529-30
31. Tytherleigh MG, Warren BF, Mortensen NJ. Management of early rectal cancer. Br J Surg 2008;95(4):409-23
32. Allaix ME, Arezzo A, Caldart M, et al. Transanal endoscopic microsurgery for rectal neoplasms: experience of 300 consecutive cases. Dis Colon Rectum 2009;52(11): 1831-6
33. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985;312(23):1465-72
34. Tveit KM, Guldvog I, Hagen S, et al. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br J Surg 1997;84(8):1130-5
35. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324(11):709-15
36. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264(11):1444-50
37. Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000;92(5):388-96
38. Tepper JE, O'Connell MJ, Petroni GR, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 1997;15(5):2030-9
39. Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control-final report of intergroup 0114. J Clin Oncol 2002;20(7):1744-50
40. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26(30):4906-11
41. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 2010;21(9):1743-50
42. Bujko K, Glynne-Jones R, Bujko M. Adjuvant chemotherapy for rectal cancer. Ann Oncol 2010;21(12):2443
43. Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007;25(28):4379-86
44. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711-17
45. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331(8):502-7
46. Smalley SR, Benedetti JK, Williamson SK, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006;24(22):3542-7
47. Kim TW, Lee JH, Lee JH, et al. Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys 2011;81(4):1025-31
48. Lee JH, Lee JH, Ahn JH, et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol 2002;20(7):1751-8
49. Willett CG, Badizadegan K, Ancukiewicz M, et al. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999;42(2):167-73
50. Gunderson LL, Callister M, Marschke R, et al. Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status. Gastrointest Cancer Res 2008;2(1):25-33
51. Vonk DT, Hazard LJ. Do all locally advanced rectal cancers require radiation? A review of literature in the modern era. J Gastrointest Oncol 2010;1(1):45-54
52. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351(17):1731-40
53. Tepper JE, O'Neil BH. Minimizing therapy and maximizing outcomes in rectal cancer. J Clin Oncol 2011;29(35):4604-6
54. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001;19(1):157-63
55. Gosens MJ, Klaassen RA, Tan-Go I, et al. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res 2007;13(22 Pt 1):6617-23
56. Wang C, Zhou ZG, Yu YY, et al. Occurrence and prognostic value of circumferential resection margin involvement for patients with rectal cancer. Int J Colorectal Dis 2009;24(4):385-90
57. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008;26(2):303-12
58. Chemotherapy alone or chemotherapy plus radiation therapy in treating patients with locally advanced rectal cancer undergoing surgery. Available from: http://clinicaltrials.gov/show/NCT01515787
59. Twelves C, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352(26):2696-704
60. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27(19):3109-16
61. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336(14):980-7
62. Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA 2000;284(8):1008-15
63. Colorectal Cancer Collaborative G. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001; 358(9290):1291-304
64. Wong RK, Tandan V, De Silva S, et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007(2):CD002102
65. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345(9):638-46
66. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246(5):693-701
67. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12(6):575-82
68. Birgisson H, Påhlman L, Gunnarsson U, et al. Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy. Br J Surg 2008;95(2):206-13
69. Birgisson H, Påhlman L, Gunnarsson U, et al. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005;23(34):8697-705
70. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373(9666):811-20
71. Stephens RJ, Thompson LC, Quirke P, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 2010;28(27):4233-9
72. Boulis-Wassif S, Gerard A, Loygue J, et al. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Cancer 1984;53(9):1811-18
73. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355(11):1114-23
74. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24(28):4620-5
75. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93(10):1215-23
76. Ngan SY, Fisher R, Burmeister BH, et al. Promising results of a cooperative group phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801). Dis Colon Rectum 2005;48(7):1389-96
77. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30(16):1926-33
78. Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27(31):5124-30
79. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30(31):3827-33
80. Siegel R, Burock S, Wernecke KD, et al. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer 2009;9:50
81. Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010;97(4):580-7
82. Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer-the RAPIDO trial. BMC Cancer 2013;13:279
83. Fernandez-Martos C, Nogué M, Cejas P, et al. The role of capecitabine in locally advanced rectal cancer treatment: an update. Drugs 2012;72(8):1057-73
84. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13(6):579-88
85. Roh MS. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011;29(suppl); abstract 3503
86. Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAP OX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010;28(5):859-65
87. Schou JV, Larsen FO, Rasch L, et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol 2012;23(10):2627-33
88. Willett CG, Duda DG, Ancukiewicz M, et al. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist 2010;15(8):845-51
89. Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012;30(14):1620-7
90. McCollum AD, Kocs DM, Chadha P, et al. A randomized phase II trial of preoperative chemoradiotherapy with or without cetuximab in locally advanced adenocarcinoma of the rectum. J Clin Oncol 2010;28(15s(suppl):abstract 3635
91. Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 2006;24(4):656-62
92. Valentini V, De Paoli A, Gambacorta MA, et al. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092). Int J Radiat Oncol Biol Phys 2008;72(3):644-9
93. Bengala C, Bettelli S, Bertolini F, et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 2009;20(3):469-74
94. Velenik V, Ocvirk J, Oblak I, et al. Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial. Radiol Oncol 2012;46(3):252-7
95. Grimminger PP, Danenberg P, Dellas K, et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res 2011;17(10):3469-77